Following these transactions, Bobo holds 46,935.7184 shares directly, with additional holdings in indirect accounts, including 38,616.6145 shares in a 401(k) and 135,152 shares held by a trust. The company maintains robust financial health with a current ratio of 3.

Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device maker, citing concerns over its prospects in the market for Transcatheter Aortic Valve Replacement (TAVR).

Fintel reports that on January 16, 2025, Wolfe Research downgraded their outlook for Edwards Lifesciences (NYSE:EW) from Peer Perform to Underperform. Analyst Price Forecast Suggests 14.75% Upside As of December 23,

Wolfe Research adjusted its perspective on Edwards Lifesciences (NYSE:EW) shares, downgrading its rating from Peerperform to Underperform. The firm also set a price target of $60.00 for the medical technology company's stock,